| 1.Disease modeling |
| 2. Regenerative medicine: tissue engineering and organ repair |
| 3. Drug screening for toxicity, drug development and drug discovery |
| 4. Genetic therapy; treatment of intractable and genetic disorders: |
| ** Sickle cell anemia |
** Cystic fibrosis |
| ** β- Thalassemia |
** Lysch - Nyhan syndrome |
| ** Hemophilia |
** Hurler syndrome |
| ** Fanconi anemia |
** Pompe disease |
| ** Dyskeratosiscongenita |
** Wilson disease |
| ** Schwachman-Bodian-Diamond syndrome |
** Down's syndrome |
| ** Primary myelofibrosis |
** Huntington's disease |
| ** Polycythemia rubravera |
** Parkinson's disease |
| ** Epidemolysisbulosae |
** Alzheimer's disease |
| ** Retinitis pigmentosa |
** Schizophrenia |
| ** Spinal muscular atrophy |
** Ducchene muscular dystropy |
| |
** Amyotrophic lateral sclerosis |
| 5. Cell-based therapies. |
| 6. Synthesis of blood components: the following blood components have been generated from embryonic and iPSCs: |
| [a] Red blood cells [definitive and primitive erythroid cells]; can be used in severe anemia or blood loss. |
| [b] Megakaryocytes and platelets; transfusion in critical thrombocytopenia |
| [c] Dendritic cells: antigen-specific vaccines for cancer or human immunodeficiency virus (HIV) |
| [d] Natural killer cells: natural or antibody-assisted anticancer cytotoxicity |
| [e] T- lymphocytes: antigen-specific anti-cancer or anti- HIV adoptive cell transfer. |
| [f] B- lymphocytes |
| [g] Neutrophils |
| [h] Monocytes and macrophages |
